HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and foreign trade business. It has established a "1+2+3+4=1" service system and can supply L-Leucine sourced directly from multiple well-known original manufacturers. As a foreign trade service provider with independent R&D capabilities, HiSiaddi has repeatedly resolved customized L-Leucine product requirements for clients through technological transformation cooperation with manufacturers and precise insight into market demands. Below is a case study of HiSiaddi delivering customized L-Leucine solutions.
Please contact HiSiaddi customer service if you require more customized services.
The buyer is NUTRAMED Spain, a premium medical nutrition group headquartered in Madrid, Spain. With over 30 years of experience focusing on high-end clinical medical nutrition, postoperative rehabilitation oral preparations and premium sports nutrition hospital products across the Iberian Peninsula, Portugal and Italy, its products are supplied to clinical nutrition departments of public hospitals in Madrid, Spain, high-end organic pharmacy chains in Western Europe and private rehabilitation clinics. Its raw materials comply with the European EP Pharmacopoeia, US USP Pharmacopoeia, EU LFGB food access standards, REACH chemical regulations and Spain’s local AENOR medical nutrition raw material control standards. It mainly manufactures three finished products: postoperative enteral nutrition powder, sustained-release L-Leucine repair soft capsules and targeted muscle-building oral liquids for elite athletes, targeting middle-class consumers in Western Europe, postoperative patients and professional sports clubs. It ranks as a mid-to-high-end purchaser in the European amino acid raw material procurement sector.
For more than a decade, the group has consistently purchased customized L-Leucine manufactured by Evonik (Germany) and Kyowa Hakko (Japan), with an annual stable procurement volume of 32 tons of customized-specification L-Leucine. Due to multiple factors including shrinking production capacity of local European manufacturers, raised minimum order quantity for customized products to 5 tons, extended ocean shipping cycle up to 90 days and annual raw material price hikes of over 30%, the group launched a China-origin customized replacement project in 2025.
The client’s demand was not standard off-the-shelf national standard L-Leucine available on the market, but three customized targeted specifications: powder with exclusive customized particle size, ultra-low D-form chiral isomer impurities and low-moisture absorption modified refined grade, for the production of three differentiated end formulations. The client independently contacted four leading domestic amino acid fermentation manufacturers in the early stage, yet all manufacturers prioritized selling their mass-produced standard off-the-shelf grades, only capable of minor purity adjustments rather than full-set customized process implementation. After trial production, multiple equipment tests encountered mass production failures including powder delamination and agglomeration, precipitate separation in oral liquids, moisture-induced discoloration of soft capsules during storage, and unqualified in-vivo dissolution rates, forcing two automated formulation production lines of the client to intermittent shutdown. The loss from scrapped semi-finished raw materials pre-invested exceeded 78,000 Euros.
After domestic manufacturers failed to deliver the full customized solution, the client formally entrusted HiSiaddi. Leveraging its industrial chain resources for amino acids and customized process database, HiSiaddi coordinated customized formula development, production process modification, pilot verification and compliance implementation across the whole chain to deliver exclusive customized L-Leucine, and finally signed a framework order for 32 tons of annual batch-by-batch procurement.
Based on the working conditions of its three finished product production lines, the client divided customized L-Leucine into three variants with differentiated customized parameters, which constituted the core difficulties that conventional mass-production domestic manufacturers could not fully address at once:
For postoperative enteral nutrition powder production, internal control requirements for L-Leucine: D90=45~52μm, D10≥12μm, angle of repose 28°~31°, no ultrafine dust or oversized particles. After blending with whey protein and multi-vitamin dry powder, the raw material must not delaminate or form local agglomerates.
Standard domestic off-the-shelf L-Leucine either features oversized crystals with D90＞90μm, causing sedimentation and delamination during powder mixing, or excessive fine powder with D90＜25μm, leading to severe electrostatic dust and blockage of automated feeding equipment. Conventional crushing equipment of domestic manufacturers cannot lock the particle size range precisely.
Restricted by the European EP Pharmacopoeia and Spanish medical nutrition regulations, the D-Leucine chiral impurity limit is ≤0.08% (the general standard for domestic standard-grade products is ≤0.3%), with single unknown impurity ＜0.05%. Conventional domestic L-Leucine produced via fermentation plus single recrystallization cannot deeply separate chiral isomers. Excessive impurities will trigger slow degradation of active ingredients in sustained-release capsules during storage and shift dissolution curves, failing finished product sampling inspections by Spanish drug authorities.
For pH 4.0~4.6 weakly acidic sports nutrition oral liquids, the raw material requires surface modification treatment. Under 60% ambient humidity, moisture absorption weight gain within 72 hours ≤1.2%; no precipitation or floccules after standing at room temperature for 60 days in a weak acid environment. Ordinary uncoated crystalline L-Leucine readily absorbs moisture and agglomerates, with drastically reduced solubility in weakly acidic aqueous solutions. All trial samples tested by the client showed turbid precipitates in the stock solution, resulting in scrapped full batches of trial-produced oral liquid.
Four leading domestic amino acid manufacturers all possess mass production capacity for national standard / EP standard conventional L-Leucine, yet limited by fixed production line processes, crystallization equipment and refining workshop configurations, manufacturers only prefer selling standardized off-the-shelf products. If production line modification, fermentation purification adjustment and recrystallization parameter revision are required for customization, manufacturers lack R&D coordination capacity for cross-formulation customization. Some manufacturers stated minor purity adjustments were available, yet synchronous implementation of particle size screening, chiral separation and surface coating modification was impossible, leaving the client’s customized demands stalled.
With years of experience in foreign trade customized services for amino acids and in-depth familiarity with the full industrial chain processes of fermented L-Leucine in China, HiSiaddi abandoned the client’s previous strategy of single-manufacturer fixed sampling. It horizontally screened two mid-to-high-end API manufacturers with GMP clean workshops, flexibly modifiable refining sections and simulated moving bed chromatographic separation equipment: Jiangsu Jingbao Biotechnology and Shandong Fufeng Pharmaceutical. Combined with the customized parameters of the client’s three finished products, customized modifications were implemented across three links: raw material fermentation optimization, recrystallization process adjustment and post-treatment modification, following a four-step customization workflow: small-batch formula trial → lab-scale sample production → pilot mass production → full-index testing verification.
1. Maintain EP Pharmacopoeia purity (content 98.5%~101.0%) of raw fermentation stock solution; precisely control cooling rate and crystallization pH in the recrystallization section to cultivate uniform crystal grains and avoid needle-shaped fine crystals.
2. Replace conventional universal crushers with low-temperature classified airflow crushing + multi-stage screening systems in post-treatment. Two-stage screening removes oversized particles and ultrafine dust. After adjusting screening wind speed across three consecutive lab batches, measured finished product D90=48.3μm, angle of repose 29.2°, fully within the client’s customized range.
3. Add trace medicinal anhydrous tricalcium phosphate as dry flow aid modification to eliminate electrostatic agglomeration of powder. In the client’s laboratory dry powder blending test, no delamination or agglomeration occurred after mixing with whey protein and other auxiliary materials and storing for 30 days.
1. Optimize fermentation strains and adjust fermentation substrate ratios at the front end to reduce the baseline generation of D-form isomers from the source.
2. Add a simulated moving bed chiral chromatographic separation section for secondary deep separation of crude L-Leucine, replacing the traditional single recrystallization purification process to drastically strip D-Leucine impurities.
3. Conduct three times gradient temperature-controlled recrystallization for further removal of trace unknown organic impurities. Final finished product test results: D-Leucine 0.062%, maximum single unknown impurity 0.038%, better than the client’s customized threshold of ≤0.08%, meeting Spanish medical nutrition raw material access standards.
1. Adopt low-temperature anhydrous ethanol temperature-controlled recrystallization in the refining stage to reduce crystal porosity and minimize water absorption through internal capillary pores of raw materials.
2. Implement trace microcrystalline cellulose surface coating modification in a clean workshop low-temperature fluidized bed to form a dense protective thin layer on L-Leucine crystal surfaces and block water vapor adsorption from air.
3. Client’s weak acid formula compatibility test: clear stock solution with no precipitation after standing at room temperature for 90 days in pH 4.3 system; moisture absorption weight gain 1.05% under 60% humidity for 72 hours, meeting customized indicators.
Synchronously prepare customized English batch COA fully aligned with all EP Pharmacopoeia testing items in accordance with European specifications; compile supporting LFGB and REACH import filing documents, classify customs declaration categories for the three customized products separately, and customize neutral moisture-proof inner bags + export food-grade outer cartons as required to adapt to moisture-proof needs for ocean shipping.
HiSiaddi coordinated two manufacturers to produce 12kg of each of the three customized small samples, shipped via cold chain to the client’s R&D laboratory in Madrid, Spain. The client simultaneously conducted dry powder mixing tests, accelerated stability tests for soft capsules and normal-temperature storage tests for oral liquids. All physical and chemical indicators, dissolution rates and impurity tests of the three finished products passed full compliance verification. The client issued a written customized qualification confirmation letter to finalize the fixed process.
Split pilot output based on annual procurement proportions: 10 tons of powder custom grade, 14 tons of sustained-release capsule custom grade, 8 tons of oral liquid modified custom grade, totaling 32 tons scheduled for production across six batches. HiSiaddi assigned technical specialists to station at manufacturers to follow up full-process sampling inspection during production. Before delivery of each batch, a third-party EU-accredited SGS laboratory conducted full-index testing to maintain consistency between batch indicators and early small sample data and eliminate inter-batch index fluctuations.
The first batch of 5.5 tons of customized goods was loaded at Shanghai Port and shipped to Barcelona Port. Spanish customs smoothly cleared the goods after verifying full compliance documents including REACH, LFGB and batch COA. After raw material warehousing, three production lines operated at full load without any raw material-induced production failures. Finished products passed AENOR drug filing in Spain and successfully entered sales channels of public hospitals and high-end pharmacies across Spain.
1. The client fully terminated import procurement of L-Leucine from Evonik (Germany) and Kyowa Hakko (Japan), switching 100% of the annual 32 tons of raw materials to Chinese customized products. Comprehensive procurement costs decreased by 24.6%, and ocean delivery cycles were shortened from the original 90 days to 35 days.
2. Based on this customized cooperation foundation, the client’s Portuguese subsidiary raised new customized demand for high-purity injectable L-Leucine, entrusting HiSiaddi with overall coordination of customized R&D and process docking for injectable raw materials, adding annual procurement of 11 tons.
3. During the R&D phase of the client’s new children’s medical nutrition powder, HiSiaddi was commissioned in advance to conduct pre-judgment of raw material customization, matching finished product formula parameters from the production source and avoiding rework costs for subsequent mass production customization.
The vast majority of domestic L-Leucine manufacturers focus on mass production of standardized off-the-shelf products with fixed production line processes and crystallization equipment, only proficient in mass production of national standard and EP standard general grades, lacking refined customized supporting capacity targeting mid-to-high-end European medical nutrition brands. Due to differentiated formulation types, European mid-to-high-end medical nutrition enterprises impose personalized customized standards on raw material particle size, chiral impurities and powder modification, and a single universal raw material cannot adapt to multi-category finished product production. Overseas clients are unfamiliar with segmented process strengths of domestic manufacturers, and independent sourcing easily leads to customized failures and scrapped samples.
As a neutral foreign trade technical service provider, HiSiaddi bridges high-quality domestic manufacturer resources and overseas customized demands, implementing personalized customized modifications across the full chain from front-end fermentation, crystallization refining to post-treatment modification, breaking the industry limitation that manufacturers only sell off-the-shelf products. It not only helps European mid-to-high-end clients achieve localized customized procurement and cost reduction, but also assists high-quality domestic amino acid manufacturers in entering the supply chain of European high-end medical nutrition raw materials, realizing long-term win-win results for both supply and demand sides.
Please contact HiSiaddi customer service if you require more customized services.
+86-13120989737 
info@hisiaddi.com 
English
